In consensus, myocardial infarction (MI) is defined as irreversible cell
death secondary to prolonged ischemia in heart. The aim of our study was to
evaluate the therapeutic potential of anti-fibrotic human Relaxin-expressing
plasmid DNA with hypoxia response element (HRE) 12 copies (HR1)
delivered by a dendrimer type PAM-ABP polymer G0 (HR1/G0) after
MI on functional, hemodynamic, geometric, and cardiac extracellular matrix (ECM)
remodeling in rats. HR1/G0 demonstrated significantly improved
LV systolic function, hemodynamic parameters, and geometry on 1 wk and 4 wks
after MI in rats, compared with I/R group. The resolution of regional wall
motional abnormalities and the increased blood flow of infarct-related coronary
artery supported functional improvements of HR1/G0.
Furthermore, HR1/G0 polyplex showed favorable post-infarct
cardiac ECM remodeling reflected on the favorable cardiac ECM compositions.
Overall, this is the first study, which presented an advanced platform for the
gene therapy that reverses adverse cardiac remodeling after MI with a
HR1 gene delivered by a bioreducible dendrimer polymer in
the cardiac ECM.